DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
The Response filed June 25, 2026 is acknowledged.
Claims 52-62 were pending. Claim 62 is being examined on the merits. Claims 52-61 are canceled.
Response to Arguments
Applicant’s arguments filed June 25, 2026 have been fully considered.
The following rejections are WITHDRAWN in view of Applicant’s arguments and amendments to the claims:
Rejection of claims 52-53 and 59-61 under 35 USC § 101
Prior art rejections
The following rejections are MODIFIED:
Rejection of claim 62 under 35 USC § 101
Response to arguments regarding 35 USC § 101 rejections
Applicant argues that the 35 USC § 101 rejection should be withdrawn for several reasons. First, as to Step 1 of the subject matter eligibility analysis, Applicant notes that claim 62 is directed to a composition of matter (Remarks, pp. 6-7).
The Examiner agrees that claim 62 is directed to a composition of matter, but that is not dispositive as to a finding of subject matter eligibility.
As to Step 2A, Prong One, Applicant essentially argues that the claimed primer sequences are not naturally occurring RNA or genomic DNA, or an isolated nucleic acid fragment because the instant claim requires that the primer sets are configured for RT-PCR that uses RNA as a template and that genomic DNA is not reverse transcribed (Remarks, pp. 7-8).
The Examiner disagrees. While it is true that genomic DNA is not reverse transcribed, primers that are used for RT-PCR will comprise sequences that are identical to genomic DNA sequences. That is, genomic DNA is double-stranded and RNA is transcribed from the coding DNA strand. Thus, the RNA strand is complementary to the coding genomic DNA strand, and is comprised of ribonucleotides. Reverse transcribing that RNA requires a primer that is complementary to the RNA strand. Since the RNA is itself complementary to the coding genomic DNA strand, the reverse transcription primer will have a sequence that is complementary to the complement of the coding genomic DNA strand – in other words, the RT primer will have a sequence that is identical to a sequence in the coding genomic strand. Then, performing PCR will require using the RT primer, which comprises a sequence identical to the coding genomic strand, as noted, and a second primer, which comprises a sequence that is identical to the complement of the coding genomic strand. Thus, RT-PCR primers comprise isolated sequences of genomic DNA. Further, while the primers are comprised within a kit which includes other components, at least some of the other components are also products of nature.
Applicant further argues that claim 62 is directed to a kit that includes conditioning reagents and RNA access components and thus the primers have a specific functional role in the kit (Remarks, pp. 8-9).
The Examiner disagrees. First, as noted below, there are at least some embodiments of claim 62 where the conditioning reagents and RNA access components are themselves products of nature. Second, while Applicant has not expressly stated this argument, it seems that Applicant is implying that the kit components have markedly different characteristics compared to their naturally occurring counterparts. However, there is no evidence that the claimed composition comprises markedly different characteristics. MPEP 2106.04(c)(II)(C) states “to show a marked difference, a characteristic must be changed as compared to nature, and cannot be an inherent or innate characteristic of the naturally occurring counterpart or an incidental change in a characteristic of the naturally occurring counterpart”. Further, MPEP 2106.04(c)(II)(C)(2) states …
PNG
media_image1.png
249
769
media_image1.png
Greyscale
Thus, the instantly claimed primers lack markedly different characteristics from their naturally occurring counterparts, and the other components in the kit (conditioning reagents and RNA access components) do not have any characteristic that is “changed as compared to nature”, nor does assembling these various components into a kit create a change in characteristic.
As to Step 2A, Prong Two, Applicant argues that the additional elements integrate the judicial exception into a practical application because “[t]he claimed kit includes conditioning reagents, RNA access components, and a detection agent including RT-[PCR/LAMP] primer sets configured for reverse-transcription amplification of the … biomarker. These elements do not merely store or package a natural product. Rather, the claim recites a specific kit configuration for accessing … and detecting a short-lived biomarker through reverse-transcription amplification” (Remarks, pp. 9-11).
The Examiner disagrees. As noted above, the judicial exceptions in claim 62 include the primers, as well as at least some embodiments of the conditioning reagents and RNA access components. MPEP 21064.04 (II)(A)(2) states “if there are no additional claim elements besides the judicial exception, or if the additional claim elements merely recite another judicial exception, that is insufficient to integrate the judicial exception into a practical application … eligibility ‘cannot be furnished by the unpatentable [judicial exception]’. For a claim reciting a judicial exception to be eligible, the additional elements (if any) in the claim must ‘transform the nature of the claim’ into a patent-eligible application of the judicial exception”. As noted above, the judicial exceptions in claim 62 include the primers, as well as at least some embodiments of the conditioning reagents and RNA access components. The only limitation in claim 62 that is not a judicial exception is the kit. However, assembling reagents into kits does not seem to impose any meaningful limit on the claim. For example, assembling various reagents into kits doesn’t even require that those reagents are used together.
Applicant further argues that the claimed invention is directed to a particular improvement in viable-cell detection by providing a kit configured to detect a short-lived RNA biomarkers (Remarks, p. 12).
The Examiner disagrees. It is not clear that the claimed invention is directed to an improvement in viable-cell detection as Marquez1 teaches detecting RPR RNA conserved region 5 (for example, see the prior art rejections in the Non-Final Office Action mailed March 25, 2026). Thus, such an assay was already known in the art prior to the effective filing date of the instant invention.
Applicant argues that claim 62 includes additional elements that apply or use the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technology environment (Remarks, p. 12).
The Examiner disagrees. The only additional (i.e., non-judicial exception) element in claim 62 is the kit. It is not clear how assembling primers and reagents into kits is applying the judicial exception in a meaningful way.
As to Step 2B, Applicant argues that claim 62 is not merely a generic kit containing nucleotides, but rather requires the ordered combination of conditioning reagents, RNA access components and primer sets configured for reverse-transcription amplification of the short-lived biomarker. Thus, Applicant concludes that “the invention does significantly more than the alleged judicial exception” (Remarks, pp. 14-15).
The Examiner disagrees. MPEP 2106.05 (I) states “[a]n inventive concept ‘cannot be furnished by the unpatentable [judicial exception] itself … Instead, an ‘inventive concept’ is furnished by an element or combination of elements that is recited in the claim in addition to (beyond) the judicial exception”. As noted above, the only additional (i.e., non-judicial exception) element in claim 62 is the kit, and as noted in the rejection below, assembling nucleotides and various reagents into kits is routine and conventional in the art. Whether the judicial exceptions are arranged in the kit in an “ordered combination” is not relevant to this inquiry as the judicial exceptions themselves cannot supply the inventive concept.
Claim Interpretation
The claim 62 recitation “for determining the presence of viable cells in an (analysis) sample” (preamble) is a statement of intended use and does not limit the claim.
When claim language recites an intended use, the claim must be evaluated to determine whether the statement of intended use results in a structural difference between the claimed invention and the prior art. If there is no such structural difference, then the intended use does not limit the claim. MPEP 2111.02 (II). Here, there is no structural difference between a kit that comprises reagents for detecting viable cells, and a kit that comprises the same reagents, but for some other use, and thus these statements do not impose a structural difference on claims.
The claim 62 recitations of “short-lived … RNA [molecules/biomarker]”, “short-lived RNA molecules in the analysis sample”, and “c) … the short-lived … biomarker that is present in viable cells with more than 300 copies per cell, and has nucleic acid sequences in more than one kingdom …, and is not abundant in non-viable cells” are functional limitations.
These limitations are construed as requiring that the detection agent binds/hybridizes to
biomarkers with the required characteristics, and specifically to all of the CR1, CR2, CR3, CR4 and CR5 conserved regions of RPR.
The claim 62 recitation that the detection agent/primer sets “detect[] the short-lived RNA biomarker that is present in viable cells with more than 300 copies per cell, (ii) has one or more nucleic acid sequences in more than one kingdom of life, and … which is found in viable cells and is not abundant in non-viable cells” are functional properties of the detection agent/primer sets. In the instant context of detection of nucleic acid biomarkers, the only function that the detection oligonucleotide has is to hybridize to the target biomarker oligonucleotide, which is RPR2. Thus, the criteria describe the functional ability of a detection agent/primer set to hybridize to RPR, and a detection agent/primer set that does so inherently satisfies these criteria3.
The claim 62 recitation of “wherein the primer sets anneal to a complete or partial sequence of the CR1, CR2, CR3, CR4 and CR5 conserved regions” is being interpreted as requiring that the primer sets anneal to each of CR1 and CR2 and CR3 and CR4 and CR5. Thus, claim 62 comprises an embodiment, e.g., with 5 primer sets, where primer set 1 anneals to CR1, primer set 2 anneals to CR2, primer set 3 anneals to CR3, primer set 4 anneals to CR4 and primer set anneals to CR5. However, claim 62 does not comprise an embodiment, e.g., with one primer set, where the first primer of the set anneals to CR1 and the second primer of the set anneals to CR5, thus creating an amplification product spanning CR1 through CR5 and comprising all of the intervening sequences, because such a primer set does not anneal to each of CR1, CR2, CR3, CR4 and CR5.
The claim 62 recitation of “wherein the one or more RT-PCR or RT-LAMP primer sets are configured for reverse-transcription amplification of the short-lived RNA biomarker” is being construed as reciting a property of the primer sets. That is, when claim language recites a “wherein” clause or “configured for” language, the claim must be evaluated to determine whether that language further limits the claim to a particular structure. MPEP 2111.04 (I). If there is no such structural difference, then the wherein clause does not limit the claim. Here, there is no structural difference between primers that are “configured for reverse-transcription amplification of the short-lived RNA biomarker” and primers that are configured for any other amplification method, and thus these statements do not impose a structural difference on claims.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claim 62 is rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception without significantly more.
Eligibility is considered in light of MPEP 2106 III, which incorporates the 2019 Revised Patent Subject Matter Eligibility Guidance (2019 PEG) published on January 17, 2019 (84 Fed. Reg. 50) and is clarified in the October 2019 Update.
As can be seen in the MPEP 2106 III Figure, eligibility analysis requires one to address the following questions: (i) Step 1 – Is the claim directed to one of the four statutory categories (i.e., process, machine, manufacture or composition of matter); (ii) Step 2A – Is the claim directed to a judicial exception (i.e., a natural phenomenon, law of nature or abstract idea); and (iii) Step 2B – does the claim recite additional elements that amount to significantly more than the judicial exception. In addition, as can be seen in the MPEP 2106.04 II Figure, Step 2A is a two-prong inquiry, with Prong One asking whether the claims recite a judicial exception (i.e., an abstract idea, natural phenomenon or law of nature) and Prong Two asking whether the claims recite additional elements that integrate the judicial exception into a practical application.
In this case, as to Step 1, claim 62 is directed to one of the four statutory categories since they are drawn to a composition of matter.
The analysis cannot be streamlined, so the claims are considered with respect to Step 2A.
With respect to Prong One of Step 2A, claim 62 recites a judicial exception. Specifically, the primers in claim 62 are a product of nature (i.e., a natural phenomenon). The claims require oligonucleotides that each bind to a particular RNA molecule. While the primer sequences themselves are not specified, they would encompass fragments of the naturally occurring complementary genomic DNA strand. It is not clear that these primers exist in nature, but these oligonucleotides, are, nevertheless, judicial exceptions because they are derived from naturally occurring nucleic acids (see, e.g., Marquez, Table 1: CRIV#2 sequence; p. 750, left col., para. 3) and possess no structural or functional differences relative to their naturally occurring counterpart. For example, the oligonucleotides are not required to include a label or non-naturally occurring nucleotides, nor do they have functions not possessed by naturally occurring nucleic acids. As well, MPEP 2164.04(b)(i) identifies isolated nucleic acids having no structural or functional differences from naturally occurring nucleic acids as an example of a patent-ineligible natural product.
In addition, as discussed in MPEP 2016.04(b)(II), “[P]roduct of nature exceptions include both naturally occurring products and non-naturally occurring products that lack markedly different characteristics from any naturally occurring counterpart.” See Ambry Genetics, 774 F.3d at 760, 113 USPQ2d at 1244. In this case, the claimed oligonucleotides have no functional differences relative to their naturally occurring counterparts since both the claimed and naturally occurring molecules hybridize to complementary nucleic acids.
Further, additional products of nature include the conditioning reagent, e.g., cell culture media4, and the lysis reagent, e.g., lysozyme and proteases5.
In view of the foregoing, claim 62 clearly recites judicial exceptions. With respect to Prong Two of Step 2A, the claims do not recite additional elements that integrate the judicial exceptions into a practical application for the following reason, as claim 62 needs not include any elements other than the judicial exceptions themselves. In addition, to the extent that “kit” is construed to require something additional, such as assembling the various oligonucleotides into container(s), this constitutes insignificant extra-solution activity as described in the 2019 PEG and MPEP 2106.05(g).
Thus, the answer to step 2A is “Yes, the claims are directed to a judicial exception,” and the analysis moves to Step 2B, which asks if the additional elements in the claim amount to significantly more than the judicial exception.
In this case, claim 62 does not include additional elements that are sufficient to amount to significantly more than the judicial exception because assembling nucleotides into kits was routinely taught in the art prior to the effective filing date of the claimed invention (e.g., see Kubit6, cited in the prior art rejections in the Non-Final Office Action mailed March 25, 2026). Therefore, the additional elements in claim 62 are not non-routine or unconventional.
In view of the foregoing, claim 62 is rejected under 35 U.S.C. 101 as being drawn to a judicial exception without significantly more.
Conclusion
Claim 62 is being examined and is rejected. No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CAROLYN GREENE whose telephone number is (571)272-3240. The examiner can normally be reached M-Th 7:30-5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CAROLYN L GREENE/Primary Examiner, Art Unit 1681
1 Marquez was cited in the PTO-892 Notice of References Cited mailed August 8, 2025.
2 See Cooper (The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Detection of Nucleic Acids and Proteins. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9916): “[n]ucleic acid hybridization provides a means for detecting DNA or RNA sequences that are complementary to any isolated nucleic acid” (p. 1, para. 3).
3 See MPEP 2112 (I), which states that “the claiming of a new … function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable”. Also see MPEP 2112.01 (I), which states that “[w]here the claimed and prior art products are identical or substantially identical in structure or composition … a prima facie case of either anticipation or obviousness has been established”, and MPEP 2112.01 (II), which states that “[p]roducts of identical chemical composition cannot have mutually exclusive properties”. Finally, see MPEP 707 which states that the examiner may rely upon admissions by the application in rejecting claims as to any matter affecting patentability.
4 The specification teaches that the “conditioning reagent” includes “natural cell culture media” (para. 54).
5 The specification teaches that the “lysis reagent” includes “enzymes such as lysozyme or proteases” (para. 74).
6 Kubit was cited in the PTO-892 Notice of References Cited mailed August 1, 2024.